| 영문 | Behcet disease | 한글 | 베체트병 |
|---|---|---|---|
| 설명 | 심한 포도막염, 망막혈관염, 시각신경위축, 구강-성기의 아프타성 궤양, 광범위한 혈관염의 징후와 증상을 나타낸다. 원인불명의 희귀한 병으로 젊은 남자에게 잘 발생한다. |
||
| 영문 | congenital heart disease | 한글 | 선천심장병 |
|---|---|---|---|
| 설명 | 선천적으로 심장의 구조에 이상이 있는 병. |
||
| 영문 | venereal disease, sexually transmitted diseases | 한글 | 성병 |
|---|---|---|---|
| 설명 | 보편적으로 성교 또는 성기접촉에 의해 걸리는 접촉 전염병으로 매독, 임질, 무른궤양, 샅굴육아종 등을 말한다. 치료는 원인균에 따른 적절한 항생요법이다. |
||
| 영문 | VDRL(venereal disease research laboratory) | 한글 | 성병 연구실험실 |
|---|---|---|---|
| 설명 | 매독균의 reagin에 대한 항체. 매독의 선별검사로 사용되며 매독 치료에 대한 반응 여부와 치료효과 판정에도 사용된다. 매독외에도 전신성홍반성낭창, 류마티스관절염 등에서도 양성으로 나타날 수 있다. |
||
| 영문 | hemolytic disease of newborn | 한글 | 신생아용혈병 |
|---|---|---|---|
| 설명 | 신생아에서 적혈구가 비정상적으로 많이 파괴되는 병으로 태아적모구증(erythroblastosis fetalis)와 같은 뜻으로 쓰인다. 이것은 어머니에게서 생산된 신생아나 태아의 적혈구에 대한 항체가 태반을 건너와서 태아의 적혈구와 결합하여서 생기는 용혈성빈혈을 이르는 말. 즉 신생아나 태아의 적혈구의 항체가 어머니의 몸에서 생산이 되고 이것이 태반을 통해서 태아에게 넘어가서 태아의 적혈구와 결합을 하고 이 항체와 결합한 적혈구는 파괴가 되어서 빈혈이 생긴 것을 태아적모구증이라고 한다. 이것은 Rh 적모구증(Rh erythroblastosis)와 ABO 적모구증(ABO erythroblastosis)로 나눌 수가 있다. |
||
| CRD | carbohydrate-recognition domain; chronic renal disease; chronic respiratory disease; child restraint... |
|---|---|
| TSA | technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso... |
| TSTA | toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen... |
| ECG | Electro-Cardio-Graphy(-Gram); 심전도 = EKG 1. Conducting System Structu... |
| AHD | acquired hepatocerebral degeneration; acute heart disease; antihyaluronidase; antihypertensive drug;... |
| carcinoembryonic antigen | <tumour marker> Antigen found in blood of patients suffering from cancer of colon and some other diseases, that is otherwise normally found in foetal gut tissue. (19 Jan 1998) |
|---|---|
| macrophage-1 antigen | An adhesion-promoting leukocyte surface membrane heterodimer. The alpha subunit consists of the CD11b antigen and the beta subunit of the CD18 antigen (antigens, CD18). The antigen, which is an integrin, functions both as a receptor for complement 3 and in cell-cell and cell-substrate adhesive interactions. (12 Dec 1998) |
| V antigen | Viral antigen that is intimately associated with the virus particle, is protein in nature, has multiple antigenicities, and is strain-specific; antibody to such antigen is demonstrable as protective or neutralizing antibody. (05 Mar 2000) |
| variable antigen | <immunology> Term usually applied to the surface antigens of those parasitic or pathogenic organisms that can alter their antigenic character to evade host immune responses. (See antigenic variation). (18 Nov 1997) |
| G antigen | An antigenic glycoprotein frequently associated with viral surfaces. Origin: Ger. Gebundenes, bound (05 Mar 2000) |
| major histocompatibility antigen | <immunology> A set of plasmalemmal glycoprotein antigens involved in rapid (e.g. 7 days in the mouse) graft rejection and other immune phenomena. The minor histocompatibility antigens are involved in much slower rejection phenomena. The major antigens show remarkable polymorphism and occur as Class I and Class II types in mammals, birds may have a Class III molecule as well. See: histocompatibility antigens, MHC restriction. (18 Nov 1997) |
| P antigen | <haematology, immunology> Antigenic determinant on the surface of human red blood cells to which the Donath Landsteiner antibody reacts. This antibody binds in the cold (a cold IgG), but elutes from red cells at 37쵣, is particularly associated with tertiary syphylis and its binding causes paroxysmal nocturnal haemoglobinuria. (18 Nov 1997) |
| R antigen | Those that produce active haemolysins (O and S) which cause a zone of clear haemolysis on the blood agar medium in the area of the colony; beta-haemolytic streptococci are divided into groups (A to O) on the basis of cell wall C carbohydrate (see Lancefield classification); Group A (in the strains pathogenic for man) comprises more than 50 types (designated by Arabic numerals) determined by cell wall M protein, which seems to be associated closely with virulence and is produced chiefly by strains with matt or mucoid colonies, in contrast to nonvirulent, glossy colony-producing strains; other surface protein antigens such as R and T (T substance), and the nucleoprotein fraction (P substance) seem to be of less importance. The more than 20 extracellular substances elaborated by strains of beta-haemolytic streptococci include erythrogenic toxin (elaborated only by lysogenic strains), deoxyribonuclease (streptodornase), haemolysins (streptolysins O and S), hyaluronidase, and streptokinase. Synonym: haemolytic streptococci. (05 Mar 2000) |
| gene rearrangement, alpha-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors. (12 Dec 1998) |
| gene rearrangement, beta-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors. (12 Dec 1998) |
| gene rearrangement, delta-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the delta-chain of antigen receptors. (12 Dec 1998) |
| gene rearrangement, gamma-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors. (12 Dec 1998) |
| M antigen | An antigen found in the cell of Streptococcus pyogenes; associated with virulence. See: beta-haemolytic streptococci. (05 Mar 2000) |
| receptor-CD3 complex, antigen, T-cell | Molecule composed of the non-covalent association of the T-cell antigen receptor (receptors, antigen, T-cell) with the CD3 complex (antigens, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex. (12 Dec 1998) |
| receptors, antigen | Molecules on the surface of b- and T-lymphocytes that recognise and combine with specific antigens. (12 Dec 1998) |